Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2024
Filing Date: May 28, 2024
This filing serves to disclose a material corporate event regarding the company's listing status on the Nasdaq Stock Market. The registrant is a foreign private issuer based in Jerusalem, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on a specific regulatory event and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the receipt of a determination letter from Nasdaq staff regarding the company's failure to meet shareholders' equity listing requirements. Consequently, the company has been scheduled for a hearing to present a plan for regaining compliance.
Guidance, Outlook, and Risks
- Regulatory Risk: The company faces the risk of delisting if it cannot present and execute a satisfactory plan to regain compliance with Nasdaq shareholders' equity requirements.
- Management Commentary: The filing references a press release issued on May 24, 2024, which details the Nasdaq determination and the upcoming hearing. No specific financial guidance or operational outlook is provided in this text.
- Unusual Items: The receipt of the Nasdaq determination letter is the sole unusual item reported in this document.
Key Facts for Investor Verification
- Verify the specific shareholders' equity threshold the company failed to meet as outlined in the Nasdaq determination letter.
- Confirm the date and status of the hearing scheduled to present the compliance plan.
- Review the full text of the press release (Exhibit 99.1) for details on the proposed plan to regain compliance.
- Monitor subsequent filings for updates on the hearing outcome and any potential delisting notices.